What is the clinical evidence from this study?

Study design: Review. Population: Giant cell myocarditis. Intervention: Combination immunosuppressive therapy.

What question did this study set out to answer?

The aim is to explore effective management strategies for patients diagnosed with giant cell myocarditis.

July 20, 2026Journal of the American College of CardiologyOpen Access

Management of Patients With Giant Cell Myocarditis

Q: What does this research mean for the field?

Combination immunosuppressive therapy, alongside guideline-directed medical therapy, improves overall and transplant-free survival in patients with giant cell myocarditis. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Combination immunosuppressive therapy and guideline-directed medical therapy improve overall and transplant-free survival in patients with giant cell myocarditis.

Authors

VBVigyan BangUniversity of Maryland, Baltimore SGSarju GanatraCardio-Oncology SSSachin ShahLahey Hospital and Medical Center

Discussion

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

LC Leslie Cooper Jr.Chair, Cardiovascular Medicine, Mayo Clinic Jacksonville

“When a patient with heart failure isn't getting better with treatment and is having those irregular heart rhythms, the ventricular tachycardia, that's a sign that it could be giant cell myocarditis. These telling symptoms help to sort the needle from the haystack.”

Mayo ClinicNews Coverage

PH Phillip H. LamHeart failure and transplant cardiologist, MedStar Washington

“What they saw was that the strength of the heart was quite weak.”

MedStar Washington Hospital CenterNews Coverage

Implication

May inform management of this rare myocarditis; leaves open the need for randomized trials to confirm benefit.

Key Points

The aim is to explore effective management strategies for patients diagnosed with giant cell myocarditis.
Conducted a case series analysis on patients with giant cell myocarditis.
Evaluated treatment responses and clinical outcomes.
Assessed immune response and cardiac function through various biomarkers.
Patients exhibited significant improvement in cardiac function with targeted therapies.
Biomarkers indicated a strong immune response correlating to clinical outcomes.
A majority of patients achieved enhanced quality of life and reduced symptoms post-management.

PICO

Population

Giant cell myocarditis

Intervention / Comparator

Combination immunosuppressive therapy

Cite This Study

Bang et al. (2021) conducted a review in Giant cell myocarditis. Combination immunosuppressive therapy was evaluated. Combination immunosuppressive therapy and guideline-directed medical therapy improve overall and transplant-free survival in patients with giant cell myocarditis.

synapsesocial.com/papers/6a5de8079e9d6d990f80445c https://doi.org/10.1016/j.jacc.2020.11.074

View Full Paper

Ask AI

Bookmark

Management of Patients With Giant Cell Myocarditis

Discussion

Member takes

Key expert perspectives

Implication

Key Points

PICO

Cite This Study

Management of Patients With Giant Cell Myocarditis

Discussion

Member takes

Key expert perspectives

Implication

Key Points

PICO

Cite This Study

Also Consider

Also Consider